P/E ratio for Samsung Biologics (207940.KS)
P/E ratio as of April 2024 (TTM): 64.4
According to Samsung Biologics 's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 64.4408. At the end of 2022 the company had a P/E ratio of 71.7.
P/E ratio history for Samsung Biologics from 2016 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | 71.7 | -53.28% |
| 2021 | 153 | -33.08% |
| 2020 | 229 | 60.64% |
| 2019 | 143 | 27.85% |
| 2018 | 112 | -141.56% |
| 2017 | -269 | 447.92% |
| 2016 | -49.0 |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.